Reuters: "Pharma stocks could see turbulence from U.S. Senate drug-price hearing"

By in
Reuters: "Pharma stocks could see turbulence from U.S. Senate drug-price hearing"

Excerpt from Reuters quoting DataTrek’s Nick Colas:

…. “Nicholas Colas, co-founder of DataTrek Research, last week recommended that investors underweight healthcare stocks in part because the companies “are in the sights of both Democrat and Republican lawmakers, an important point as the 2020 presidential campaign cycle gets under way.”

“They are an easy target because the electorate really dislikes the American healthcare system,” Colas said in a note….”

Read the full article here on Reuters!